Minapharm Pharmaceuticals results, Fiscal year 2022
Net profit, assets, equity and cash flow for Fiscal year 2022, against the same period a year earlier, from the published financial statements.
Net profit613 millionEGP · +31.4% vs the same period a year earlier
Total assets6.81 billionEGP · +65.8% vs the same period a year earlier
Shareholders' equity3.04 billionEGP · +56.5% vs the same period a year earlier
Operating cash flow562 millionEGP · +173.0% vs the same period a year earlier
In short
- Minapharm Pharmaceuticals's net profit for Fiscal year 2022 was about 613 million EGP, up +31.4% from 466 million EGP in Fiscal year 2021.
- Total assets at the end of Fiscal year 2022 were about 6.81 billion EGP, and shareholders' equity about 3.04 billion EGP.
- Operating cash flow for Fiscal year 2022 was positive at 562 million EGP.
Key lines against the same period a year earlier
This periodFiscal year 2021Change
Net profit613 million466 million+31.4%
Gross profit1.61 billion1.26 billion+27.6%
Total assets6.81 billion4.11 billion+65.8%
Total liabilities3.77 billion2.16 billion+74.1%
Shareholders' equity3.04 billion1.94 billion+56.5%
Total liabilities and equity6.81 billion4.11 billion+65.8%
Operating cash flow562 million206 million+173.0%
Investing cash flow-1.16 billion-389 million−198.8%
Financing cash flow994 million156 million+539.0%
Net change in cash179 million-27.59 million+749.5%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version.
Minapharm Pharmaceuticals's Q3 2026 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy